Drug Profile
Research programme: skin disease therapeutics - Evotec SE/Toronto Innovation Acceleration Partners
Alternative Names: LAB150Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Evotec AG
- Developer Evotec SE; Toronto Innovation Acceleration Partners
- Class Skin disorder therapies
- Mechanism of Action Kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Atopic dermatitis; Netherton Syndrome
Most Recent Events
- 07 Dec 2022 Early research is still ongoing for Atopic dermatitis and Netherton Syndrome in Germany
- 28 Mar 2022 No recent reports of development identified for research development in Atopic-dermatitis in Germany (Topical)
- 28 Mar 2022 No recent reports of development identified for research development in Netherton-Syndrome in Germany (Topical)